These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 37081314)
1. Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery. Tanishima Y; Takahashi K; Nishikawa K; Ishikawa Y; Yuda M; Tanaka Y; Matsumoto A; Yano F; Eto K Esophagus; 2023 Oct; 20(4):651-659. PubMed ID: 37081314 [TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of nodal status and lymphovascular invasion in patients undergoing neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Miyata H; Sugimura K; Kanemura T; Takeoka T; Sugase T; Yasui M; Nishimura J; Wada H; Akita H; Yamamoto M; Hara H; Shinno N; Omori T; Yano M Dis Esophagus; 2024 Aug; 37(9):. PubMed ID: 38693752 [TBL] [Abstract][Full Text] [Related]
3. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma. Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154 [TBL] [Abstract][Full Text] [Related]
4. Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy. Oguma J; Ishiyama K; Kurita D; Kanematsu K; Kubo K; Utsunomiya D; Yamamoto S; Honma Y; Kato K; Daiko H Esophagus; 2023 Apr; 20(2):215-224. PubMed ID: 36565340 [TBL] [Abstract][Full Text] [Related]
5. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma. Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393 [TBL] [Abstract][Full Text] [Related]
6. Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery. Oguma J; Ishiyama K; Kurita D; Kanematsu K; Fujii Y; Kubo K; Yamamoto S; Honma Y; Kato K; Daiko H Esophagus; 2022 Apr; 19(2):214-223. PubMed ID: 34757482 [TBL] [Abstract][Full Text] [Related]
7. The area of residual tumor predicts esophageal squamous cell carcinoma prognosis following neoadjuvant chemotherapy. Adachi M; Aoyama N; Kojima M; Sakamoto N; Miyazaki S; Taki T; Watanabe R; Matsuura K; Kotani D; Kojima T; Fujita T; Tabuchi K; Ishii G; Sakashita S J Cancer Res Clin Oncol; 2023 Jul; 149(8):4663-4673. PubMed ID: 36201027 [TBL] [Abstract][Full Text] [Related]
8. Risk prediction of esophageal squamous cell carcinoma recurrence in patients who underwent esophagectomy after receiving neoadjuvant treatment: a nationwide retrospective study in Japan. Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y Esophagus; 2023 Jul; 20(3):465-473. PubMed ID: 37029845 [TBL] [Abstract][Full Text] [Related]
9. How does presurgical chemotherapy influence the efficiency of treatment for esophageal cancer recurrence after curative esophagectomy? Taniyama Y; Sakurai T; Hikage M; Okamoto H; Sato C; Takaya K; Unno M; Kamei T Thorac Cancer; 2019 Apr; 10(4):769-774. PubMed ID: 30756477 [TBL] [Abstract][Full Text] [Related]
10. Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma. Nakaya S; Ogawa R; Hayakawa S; Fujihata S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S World J Surg Oncol; 2021 Jul; 19(1):217. PubMed ID: 34281546 [TBL] [Abstract][Full Text] [Related]
11. The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. Aoyama S; Motoori M; Yamasaki M; Shiraishi O; Miyata H; Hirao M; Takeno A; Sugimura K; Makino T; Tanaka K; Hamakawa T; Yamashita K; Kimura Y; Fujitani K; Yasuda T; Yano M; Doki Y Esophagus; 2023 Apr; 20(2):225-233. PubMed ID: 36494496 [TBL] [Abstract][Full Text] [Related]
12. Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma. Sugase T; Kanemura T; Takeoka T; Matsuura N; Masuike Y; Shinno N; Hara H; Kitakaze M; Kubo M; Mukai Y; Sueda T; Hasegawa S; Akita H; Nishimura J; Wada H; Yasui M; Omori T; Miyata H Anticancer Res; 2024 Jan; 44(1):185-193. PubMed ID: 38159967 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. Kitasaki N; Hamai Y; Emi M; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Okada M In Vivo; 2022; 36(6):2852-2860. PubMed ID: 36309376 [TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes in patients undergoing esophagectomy following neoadjuvant DCF therapy. Takahashi K; Sakashita Y; Murahashi M; Kubota H; Shimoda M; Ishikawa Y; Tanishima Y; Kurogochi T; Yano F; Eto K J Surg Oncol; 2024 Mar; 129(4):700-707. PubMed ID: 38031881 [TBL] [Abstract][Full Text] [Related]
17. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy. Ji WH; Jiang YH; Ji YL; Li B; Mao WM Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery. Wu YY; Dai L; Yang YB; Yan WP; Cheng H; Fan MY; Gao YM; Chen KN Ann Surg Oncol; 2024 Aug; 31(8):5047-5054. PubMed ID: 38172446 [TBL] [Abstract][Full Text] [Related]
19. Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma. Matsumoto S; Wakatsuki K; Nakade H; Kunishige T; Miyao S; Tsujimoto A; Tatsumi T; Sho M Langenbecks Arch Surg; 2022 May; 407(3):965-974. PubMed ID: 34989856 [TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma. Ogawa K; Ishikawa H; Hisakura K; Hiroshima Y; Moriwaki T; Yamada T; Yamamoto Y; Akashi Y; Owada Y; Ohara Y; Enomoto T; Furuya K; Doi M; Shimomura O; Takahashi K; Hashimoto S; Sakurai H; Oda T Int J Clin Oncol; 2021 Oct; 26(10):1856-1863. PubMed ID: 34241725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]